Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ

Chicago Area News Serena Williams under fire after promoting GLP-1 weight loss medication | ChicagoNOW Taste of Lincoln Avenue returns to Chicago Chicago crime: Boy, 5, critically injured in drive-by on Near West Side, CPD says Save a Lot closing seven Chicago stores on Saturday Suburban childhood friends working their way through college keep business going after equipment theft Chicago brother allegedly shot woman he believed was involved in sister's death Police release surveillance video of suspected car involved in Aurora hit-and-run Chicago's new serial killer exhibition | ChicagoLIVE Unions speak out against outsourcing decision by Art Institute of Chicago | ChicagoLIVE Will airports ditch TSA for private security | ChicagoLIVE Nolan Wells findings, Patrick Kane returns, Bears stadium & more | Week in Review 5 killed, 4 wounded in 6 Chicago shootings from Thursday into Friday Chicago crime: Brother of woman found dead in garbage can charged in separate shooting Chicago shuts down The 50 Yard Line over safety violations 25 years later, man charged in Gary woman's stabbing death New Bronzeville mural by Chicago brothers promotes message of unity Dolton weighs future of Rucker Athletics after viral summer camp fight videos Chicago South Side sports bar shut down over 'dangerous' conditions Lollapalooza to offer THC beverages for the first time ever | ChicagoLIVE Kane Co

In parallel, Eli Lilly developed tirzepatide (Mounjaro)--a dual GLP-1 and GIP receptor agonist
This update underscores both the promise and the complexity of advancing oral GLP-1 drug technology, highlighting ongoing industry efforts to balance innovation, safety and patient-centric design as companies work to meet evolving global treatment needs
Overexpression of LAMP3 disrupts lysosomal membranes by degrading LAMP1, leading to lysosomal dysfunction and impaired autophagy [278]
Digestive Discomfort: Some users have mentioned experiencing mild digestive issues such as bloating or gas